capsaicin

(redirected from Qutenza)
Also found in: Dictionary, Medical, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Words related to capsaicin

colorless pungent crystalline compound derived from capsicum

References in periodicals archive ?
Efficacy of Qutenza (capsaicin) 8% patch for neuropathic pain: a meta-analysis of the Qutenza Clinical Trials Database.
Grunenthal, a pharmaceutical company headquartered in Stolberg, near Aachen in Germany, has agreed to acquire the commercialisation rights for Qutenza in Europe from Astellas Pharma Europe, it was reported yesterday.
Qutenza is approved by the European Medicines Agency for the treatment of peripheral neuropathic pain.
13 December 2016 - German drugmaker Grunenthal Group has entered into a definitive agreement with Japanese drugmaker Astellas Pharma Inc's Astellas Pharma Europe Ltd subsidiary for the exclusive rights to the dermal patch Qutenza (capsaicin 8%) in Europe, Middle East and Africa, the company said.
GrA1/4nenthal will hold exclusive rights for Qutenza in all 28 European Union member states, Switzerland, Iceland, Norway and Lichtenstein, and other East European, Middle East and African countries.
Biotechnology company Acorda Therapeutics Inc (Nasdaq:ACOR) revealed on Tuesday that it has completed its acquisition of two neuropathic pain management assets, Qutenza and NP-1998, from NeurogesX Inc (OTC Markets:NGSX).
The report also finds that a key factor driving growth will be the uptake of two recent entrants to the neuropathic pain market--NeurogesX/Astellas Pharma Europe's 8 percent capsaicin patch Qutenza and Johnson & Johnson/Grunenthal's dual-acting opioid analgesic Nucynta/Nucynta ER/Palexia/Palexia SR.
GRUNENTHAL TO ACQUIRE COMMERCIALISATION EMEE RIGHTS OF ASTELLAS' QUTENZA DERMAL PATCH
The company expects to use proceeds to further support commercialisation activities for Qutenza (capsaicin) 8% patch, the clinical development of the firm's lead product candidate, NGX-1998, a non-patch topically applied liquid formulation of high-concentration capsaicin, as well as general corporate purposes.
This is primarily attributed to the successive patent expiry of marketed drugs such as Lidoderm/Versatis (lidocaine patch 5%), Qutenza (capsaicin 8% patch) and Neurontin (gabapentin) along with the absence of any promising molecules in the PHN therapeutics pipeline.